Case presentation
The proband was born to a non-consanguineous family (Figure 1). He was delivered at 39 weeks gestation with normal pregnancy history. At birth he was covered with a taut shiny membrane but in a few days this membrane gradually dried and peeled off and mild dryness and scaling left behind. Skin dryness and scaling were detected at four months, which gradually intensified. He was hospitalized for a high fever at six months after taking Tetanus vaccine, diphtheria, pertussis, hepatitis B, Hemophilus influenzae, and Polio vaccines. During his hospitalization, his hepatosplenomegaly was recognized. He was evaluated for storage disease such as Niemann-Pick disease, Gaucher disease, pompe disease, and rheumatologic disease. But no positive findings were found in favor of these diseases. Following a diagnosis of elevated liver enzymes and hepatosplenomegaly on ultrasound, the patient underwent liver biopsy and was diagnosed with micronodular cirrhosis with mild macrovesicular steatosis (25 %). His liver AST and ALT enzyme levels were two to three times of the normal limit. However, ALP and bilirubin levels were normal. The patient's neuromuscular development was normal, and no muscle weakness was noticed. The blood CPK and Aldolase levels were slightly elevated. At the age of two, he had EMG-NCV with no myopathic or neuropathic indications. At this age the eye and heart examinations were normal. Other blood cholesterol, Triglyceride, and renal function tests were normal. He was diagnosed with apparent ichthyosis at age four, characterized by generalized scaly skin, particularly on the palm (Figure 2).
Two other members of the related family were also diagnosed with the same disease (Figure 1, Family II). They were a 20-year old girl and her 13-year old brother, born to a family with non-consanguineous marriage. The second case (20-year-old girl) diagnosed with ichthyosis after being born with congenital widespread skin dryness. No further clinical manifestations were noted throughout childhood. Neuronal development was normal, and there was no evidence of hypotonia. She exhibits a little ectropion. This exposes and irritates the inner eyelid surface. The levels of the AST and ALT enzymes were two to three times those found in healthy persons, although this was controlled. A slight increase in blood bilirubin was also seen. On ultrasound, the liver was normal in size but the echogenicity was relatively coarse. The patient did not undergo a liver biopsy for further investigation. Jordan's anomaly was also validated by accumulating lipid vacuoles in white blood cells (Figure 3).
The third case was the younger brother of the second case. He was 13 years old when he was diagnosed. At birth he had a slight scaling on the scalp, but it was less severe than the second case. Afterward, his skin dryness began to spread to other areas of the body (Figure 4). Additionally, he was diagnosed with ichthyosis and began using emollient creams. Similar to the first case, there was a significant rise in liver enzymes (AST and hepatomegaly and increased liver echogenicity on ultrasound). The patient underwent liver biopsy for additional study due to mild hepatomegaly. Steatosis was shown in around 70% of parenchymal cells, most of which were macrovascular. There were no signs of interface hepatitis or confluent necrosis (liver steatosis). Neither Ectropion nor entropion was seen in this case and neuromuscular examinations were normal (Table 1).
Table 1
Clinical data and molecular analysis of the patients with CDS
No.
|
Age
|
Gender
|
Phenotype
|
AST/ALT
|
Levels of Ch,TG,
|
WBC anomaly
|
1
|
4y
|
Male
|
NLSD
|
3 x normal
|
Normal
|
Jordan´s anomaly
|
2
|
20y
|
Female
|
NLSD
|
AST: 28 U/L
ALT: 30 U/L
|
Normal
|
Jordan´s anomaly
|
3
|
13y
|
Male*
|
NLSD
|
AST: 97 U/L
ALT: 124 U/L
|
Normal
|
Not tested
|
AST; aspartate aminotransferase, ALT; alanine aminotransferase
Genetic investigation
WES analysis revealed a homozygous C insertion in exon 4 of the ABHD5 gene (c.594dupC), causing a frameshift and premature termination at amino acid 209 (p.Arg119Glnfs*11) (Figure 5). Primers were designed from the region of interest, and the mutation was verified using Sanger sequencing (Figure 5). The un-relative parents were heterozygous for the mutation. Sanger sequencing of two other patients (cases number 2 and 3) using the designed primers, revealed that these patients carrying homozygous mutations in ABHD5 gene.
The ABHD5 gene contains seven exons and is located on chromosome 3. This gene codes for a 349 amino acid protein. The molecular weight of the wild-type protein is 39.095 KD. The Pfam domain search for this protein discovered an alpha/beta hydrolase fold domain that begins at amino acid 76 and ends at amino acid 334. This domain contains two amino acid residues involved in the interaction between ATGL and perilipin (Q130 and E206). ABHD5 activates PNPLA1 during the epidermal barrier development, hence determining the generation of O-acylceramide from hydroxyceramide. ABHD5 acts as an ATGL coactivator in various organs such as the liver, muscle, and immune cells, including TAG hydrolysis. The mutant protein contains 208 amino acids and has a molecular weight of 23.292 KD. This mutation alters the alpha/beta hydrolase fold domain, which is required for the enzyme to operate correctly (Figure 6).
The final models for the wild-type and mutant protein were predicted by the I-TASSER tool. Each model's confidence is quantified using a C-score generated from the importance of threading template alignments and the convergence parameters of structure assembly simulations. The C-score is typically between (-5, 2), with a higher C-score indicating a more confident model and vice versa. Figure 6, D illustrates the first model with the highest C-score for each WT and mutant protein. Eliminating the ligand-binding site residues (266, 300, 301, 327, 328) and alpha/beta hydrolase fold domain altered the protein's structure.